Completed Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma NCT03204188 Conditions B-Lymphocytic Leukemia, Chronic, B-cell Chronic Lymphocytic Leukemia, Chromosome 17 deletion, +22 more Locations National Institutes of Health Clinical Center — Bethesda, Maryland, United States View Trial Details